Bone Therapeutics Logo
BE0974280126
A14NHV
BOTHE.BR

Bone Therapeutics

Loading quotes...

Forecast

There is no analyst data available for this company.


  • Bone Biologics expects completion of patient recruitment for NB1 study by end of 2025

    Bone Biologics says it expects to complete recruitment for the first-in-human NB1 study in degenerative disc disease in Australia by the end of 2025. The multicenter study of up to 30 patients compares two NB1 concentrations with autograft; NB1 combines NELL-1 with demineralized bone matrix. The company has extended product shelf life from 12 to 18 months, is targeting 24 months, and plans additional clinical sites, an improved potency assay and an interim report after all patients reach the six-month follow-up. Bone Biologics completed a $5m capital raise at the end of June, which is expected to fund operations into Q2 2026; a 1:6 reverse stock split also took effect in June. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics
In 2024, Bone Therapeutics has already paid €0.14 in dividends. The last payout was in July 2024.

Financials

In the last quarter, Bone Therapeutics had revenue of €0 and net profit of €21.65M
(EUR) December 2025
YoY
Revenue 0 -
Gross profit 0 -
Net profit 21.65M -
EBITDA -935K -

Fundamentals

Metric Value
Market capitalization
€1.31M
Number of shares
652.86M
52-week high/low
€0.19 - €0.002
Dividends No
Beta
-1.60
P/E ratio
0.06
PEG ratio
0.00
P/B ratio
-0.67
P/S ratio
0.00

Company profile

Bone Therapeutics SA, a biotechnology company, engages in the development of cell therapy products for orthopedics and bone diseases. Its products include ALLOB, an allogeneic cell therapy product, which is in Phase I/IIa clinical trial for the treatment of delayed-union fractures and lumbar spinal fusion; and JTA-004, an intra-articular injectable that is in phase III clinical trial to treat osteoarthritic pain in the knee. Bone Therapeutics SA was incorporated in 2006 and is based in Mont-Saint-Guibert, Belgium.

Name
Bone Therapeutics
CEO
Jean-Luc Vandebroek
Headquarters Mont-Saint-Guibert,
Belgium
Website
IPO
02/06/2015
Employees 12

Ticker symbols

Exchange Symbol
Euronext
BOTHE.BR
Brussels Stock Exchange
BOTHE.BR
Düsseldorf
BT1.DU
Frankfurt
BT1.F
London
0R55.L
London Stock Exchange
0R55.L
Pnk
NINOY
Toronto Stock Exchange
TOH.V
🍪

Parqet  uses cookies. Learn more